Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer

Radiotherapy and Oncology

Volumn 120, Issue 3, 2016, Pages 441-446

  Tanderup, Kari ^a   Fokdal, Lars Ulrik ^a   Sturdza, Alina ^b   Haie Meder, Christine ^c   Mazeron, Renaud ^c   van Limbergen, Erik ^d   Jürgenliemk Schulz, Ina ^e   Petric, Primoz ^f,g   Hoskin, Peter ^h   Dörr, Wolfgang ^b   Bentzen, Søren M ⁱ   Kirisits, Christian ^b   Lindegaard, Jacob Christian ^a   Pötter, Richard ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Radiation Oncology Department   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f National Center of Cancer Care and Research   (Qatar)

^g INSTITUTE OF ONCOLOGY   (Slovenia)

^h MOUNT VERNON CANCER CENTRE   (United Kingdom)

ⁱ UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Cervical cancer; Dose effect; Image guided brachytherapy; Local control; Overall treatment time

Indexed keywords

CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CHEMORADIOTHERAPY; CLINICAL OUTCOME; COHORT ANALYSIS; CORRELATION ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GROSS TUMOR VOLUME; HIGH RISK CLINICAL TARGET VOLUME; HISTOPATHOLOGY; HUMAN; IMAGE GUIDED BRACHYTHERAPY; INTERMEDIATE RISK VOLUME; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL TREATMENT TIME; PARAMETERS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE; STATISTICAL ANALYSIS; TUMOR VOLUME; UTERINE CERVIX CANCER; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC IMAGING; EVIDENCE BASED MEDICINE; IMAGE GUIDED RADIOTHERAPY; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIATION DOSE FRACTIONATION; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING SYSTEM; TIME FACTOR; TREATMENT OUTCOME; UTERINE CERVIX TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CHEMORADIOTHERAPY; DOSE FRACTIONATION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84977582045     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.05.014     Document Type: Article

References (37)

1. [1] Perez, C.A., Grigsby, P.W., Chao, K.S., et al. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 41 (1998), 307–317.
2. [2] Perez, C.A., Grigsby, P.W., Lockett, M.A., et al. Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation. Int J Radiat Oncol Biol Phys 44 (1999), 855–866.
3. [3] Tanderup, K., Viswanathan, A.N., Kirisits, C., et al. Magnetic resonance image guided brachytherapy. Semin Radiat Oncol 24 (2014), 181–191.
4. [4] Pötter, R., Georg, P., Dimopoulos, J.C., et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100 (2011), 116–123.
5. [5] Lindegaard, J.C., Fokdal, L.U., Nielsen, S.K., et al. MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncol 52 (2013), 1510–1519.
6. [6] Nomden, C.N., de Leeuw, A.A., Roesink, J.M., et al. Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience. Radiother Oncol 107 (2013), 69–74.
7. [7] Rijkmans, E.C., Nout, R.A., Rutten, I.H., et al. Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy. Gynecol Oncol 135 (2014), 231–238.
8. [8] Gill, B.S., Kim, H., Houser, C.J., et al. MRI-guided high-dose-rate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience. Int J Radiat Oncol Biol Phys 91 (2015), 540–547.
9. [9] Chargari, C., Magne, N., Dumas, I., et al. Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys 74 (2009), 133–139.
10. [10] Prescribing, Recording, and Reporting Brachytherapy for Cancer of the Cervix. Bethesda, MD, USA, International Commission on Radiation Units and Measurements, (ICRU report 89). Bethesda; 2016.
11. [11] Haie-Meder, C., Pötter, R., Van Limbergen, E., et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74 (2005), 235–245.
12. [12] Orton, C.G., Seyedsadr, M., Somnay, A., Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation. Int J Radiat Oncol Biol Phys 21 (1991), 1425–1434.
13. [13] Dimopoulos, J.C., Pötter, R., Lang, S., et al. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol 93 (2009), 311–315.
14. [14] Mazeron, R., Castelnau-Marchand, P., Dumas, I., et al. Impact of treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemoradiation and image-guided pulsed-dose rate adaptive brachytherapy. Radiother Oncol 114 (2015), 257–263.
15. [15] Sturdza, A., Pötter, R., Fokdal, L.U., et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 120 (2016), 428–433.
16. [16] Pötter, R., Haie-Meder, C., Van Limbergen, E., et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78 (2006), 67–77.
17. [17] Hellebust, T.P., Kirisits, C., Berger, D., et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. Radiother Oncol 96 (2010), 153–160.
18. [18] Dimopoulos, J.C., Petrow, P., Tanderup, K., et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiother Oncol 103 (2012), 113–122.
19. [19] Niemierko, A., Goitein, M., Implementation of a model for estimating tumor control probability for an inhomogeneously irradiated tumor. Radiother Oncol 29 (1993), 140–147.
20. [20] Roberts, S.A., Hendry, J.H., A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity. Int J Radiat Oncol Biol Phys 41 (1998), 689–699.
21. [21] Huang, Z., Mayr, N.A., Gao, M., et al. Onset time of tumor repopulation for cervical cancer: first evidence from clinical data. Int J Radiat Oncol Biol Phys 84 (2012), 478–484.
22. [22] Majercakova, K., Pötter, R., Kirisits, C., et al. Evaluation of planning aims and dose prescription in image-guided adaptive brachytherapy and radiochemotherapy for cervical cancer: Vienna clinical experience in 225 patients from 1998 to 2008. Acta Oncol 22 (2015), 1–7.
23. [23] Tanderup, K., Nielsen, S.K., Nyvang, G.B., et al. From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer. Radiother Oncol 94 (2010), 173–180.
24. [24] Fokdal, L., Tanderup, K., Hokland, S.B., et al. Clinical feasibility of combined intracavitary/interstitial brachytherapy in locally advanced cervical cancer employing MRI with a tandem/ring applicator in situ and virtual preplanning of the interstitial component. Radiother Oncol 107 (2013), 63–68.
25. [25] Fokdal, L., Sturdza, A., Mazeron, R., et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: analysis from the retroEMBRACE study. Radiother Oncol 120 (2016), 434–440.
26. [26] Fyles, A., Keane, T.J., Barton, M., et al. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 25 (1992), 273–279.
27. [27] Girinsky, T., Rey, A., Roche, B., et al. Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 27 (1993), 1051–1056.
28. [28] Perez, C.A., Grigsby, P.W., Castro-Vita, H., et al. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 32 (1995), 1275–1288.
29. [29] Shaverdian, N., Gondi, V., Sklenar, K.L., et al. Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 86 (2013), 562–568.
30. [30] Eifel, P.J., Thames, H.D., Has the influence of treatment duration on local control of carcinoma of the cervix been defined?. Int J Radiat Oncol Biol Phys 32 (1995), 1527–1529.
31. [31] Cochrane Gynaecological Cancer Group, Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC), Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev, 1, 2010.
32. [32] Pötter, R., Dimopoulos, J., Georg, P., et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 83 (2007), 148–155.
33. [33] Charra-Brunaud, C., Harter, V., Delannes, M., et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol 103 (2012), 305–313.
34. [34] Hellebust, T.P., Tanderup, K., Lervag, C., et al. Dosimetric impact of interobserver variability in MRI-based delineation for cervical cancer brachytherapy. Radiother Oncol 107 (2013), 13–19.
35. [35] Tanderup, K., Nesvacil, N., Pötter, R., et al. Uncertainties in image guided adaptive cervix cancer brachytherapy: impact on planning and prescription. Radiother Oncol 107 (2013), 1–5.
36. [36] Georg, P., Pötter, R., Georg, D., et al. Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys 82 (2012), 653–657.
37. [37] Dyk, P., Jiang, N., Sun, B., et al. Cervical gross tumor volume dose predicts local control using magnetic resonance imaging/diffusion-weighted imaging-guided high-dose-rate and positron emission tomography/computed tomography-guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 90 (2014), 794–801.